PARIS | September 12th, 2024 – Bryan Garnier is pleased to release “Focused Ultrasound: breaking barriers in drug delivery, brain therapy and beyond”, which offers an extensive analysis of the evolving role ultrasound plays in contemporary healthcare, with recent technological advancements extending its capabilities far beyond its conventional applications.
While High-Intensity Focused Ultrasound (HIFU) has been a mainstay for over 30 years, recent breakthroughs in low- to medium-energy nonthermal ultrasound are presenting groundbreaking opportunities. These emerging technologies provide innovative alternatives or complements to conventional treatments such as surgery, drug delivery, radiation therapy, chemotherapy, and cancer immunotherapy, making them pivotal in modern healthcare.
The focused ultrasound market is experiencing significant growth at a 22% CAGR, to reach EUR 1 billion by 2029. This surge is driven by companies approaching the final stages of clinical validation, alongside robust support from established MedTech and Pharma firms providing financial and strategic backing. These include GE Healthcare, Novo Nordisk, Johnson & Jonhson, among others.
In this white paper, we provide an in-depth look at the most critical developments within this sector and identify key innovators shaping the future of ultrasound technologies.
To explore these insights and learn more about the future of ultrasound technologies, download this white paper.
Maria Vara
Equity Research Analyst | Healthcare
About Bryan, Garnier & Co
Bryan, Garnier & Co is a European growth investment bank that helps healthcare and technology companies become global champions. By combining extensive sector expertise with an entrepreneurial mindset, Bryan Garnier provides companies and their investors with independent growth strategic advice, and privileged access to buyers and capital in Europe, the US and Asia.
As a full-service investment bank, the firm offering includes private and public growth financing solutions, mergers and acquisitions (M&A) advisory, research insights, and institutional sales & execution. Founded in 1996, Bryan Garnier & Co is an independent partnership with around 200 employees located in major financial centres in Europe and the US.